US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

AgomAb Therapeutics

11.41

-0.7500-6.17%

Volume:120.33K

Turnover:1.40M

Market Cap:561.92M

PE:-2.53

High:12.85

Open:12.26

Low:11.21

Close:12.16

52wk High:17.82

52wk Low:8.75

Shares:49.25M

Float Shares:13.84M

Volume Ratio:0.99

T/O Rate:0.87%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5143

EPS(LYR):-168.1598

ROE:-39.22%

ROA:-20.58%

PB:5.30

PE(LYR):-0.07

Loading ...

Overview Company News Filings

Press Release: Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

AgomAb Therapeutics H1 EPS $(0.93)

Benzinga Earnings

Agomab FY26 H1 Net Loss Widens to €30.97 Million

Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook

THOMSON REUTERS

Agomab Therapeutics Initiated at Buy by B. Riley Securities

B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target

MT Newswires Live

Analysts’ Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)

Agomab Therapeutics Nv : B. Riley Initiates Coverage with Buy Rating; Target Price $34

THOMSON REUTERS

Agomab Therapeutics NV trading halted, volatility trading pause

NASDAQ Trade Halt Volatility Trading Pause at 03:51 Pm

European Equities Traded in the US as American Depositary Receipts Decline Friday

MT Newswires Live

Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment

Agomab announces NOV-ERA study design

Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease

Agomab Announces Design of Nov-Era Phase 2B Study With Ontunisertib in Fibrostenosing Crohn’s Disease

THOMSON REUTERS

AgomAb Therapeutics Initiated at Buy by HC Wainwright & Co.

Agomab initiated with a Buy at H.C. Wainwright

Agomab Therapeutics Nv : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $35

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon

Agomab Therapeutics holds annual general meeting, backs board reappointments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigerfiesta.com/stock/AGMB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":11.41,"timestamp":1789588800000,"preClose":12.16,"halted":0,"volume":120333,"delay":0,"changeRate":-0.061677631578947366,"floatShares":13836000,"shares":49248000,"eps":-4.51426,"marketStatus":"Pre-Mkt","change":-0.75,"latestTime":"09-17 07:25:20 EDT","open":12.26,"high":12.845,"low":11.21,"amount":1400768.656077,"amplitude":0.134457,"askPrice":14.58,"askSize":100,"bidPrice":9.26,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-4.51426,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789651800000},"marketStatusCode":1,"adr":0,"adrRate":1,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":11.41,"postHourTrading":{"tag":"盘后","latestPrice":11.41,"preClose":11.41,"latestTime":"19:30 EDT","volume":263,"amount":3005.33,"timestamp":1789601404503,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.988497797633265},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":13836000,"roa":"-20.58%","roe":"-39.22%","lyrEps":-168.159829,"volumeRatio":0.988497797633265,"shares":49248000,"dividePrice":0,"high":12.845,"amplitude":0.134457,"preClose":12.16,"low":11.21,"week52Low":8.75,"pbRate":"5.30","week52High":17.82,"institutionHeld":0,"latestPrice":11.41,"eps":-4.51426,"divideRate":0,"volume":120333,"delay":0,"ttmEps":-4.51426,"open":12.26,"prevYearClose":16,"prevWeekClose":13.06,"prevMonthClose":13.17,"prevQuarterClose":12.98,"fiveDayClose":14.96,"twentyDayClose":13.73,"sixtyDayClose":11.84},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.75,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.75,"analysts":8,"updateTime":1787716800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-09-16","current":-2.527546,"percent":0.821192,"low":-14.725744,"twenty":-11.715841,"median":-8.911516,"eighty":-7.864702,"high":-6.52172,"avg":-9.579591,"sd":2.184566,"marketCap":598855376},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-06","current":-12.944797,"twenty":-14.315694,"median":-13.869306,"eighty":-13.479283,"marketCap":692549629},{"date":"2026-03-13","current":-12.71107,"twenty":-14.294734,"median":-13.805127,"eighty":-12.961754,"marketCap":677928595},{"date":"2026-03-20","current":-11.600011,"twenty":-14.274685,"median":-13.584093,"eighty":-12.695924,"marketCap":618957093},{"date":"2026-03-27","current":-10.84065,"twenty":-14.216331,"median":-13.160447,"eighty":-12.395453,"marketCap":578505566},{"date":"2026-04-02","current":-10.748527,"twenty":-14.066263,"median":-13.052487,"eighty":-11.414439,"marketCap":574119256},{"date":"2026-04-10","current":-9.193391,"twenty":-13.930737,"median":-12.827934,"eighty":-10.709469,"marketCap":497602513},{"date":"2026-04-17","current":-10.018749,"twenty":-13.86294,"median":-12.650405,"eighty":-9.901184,"marketCap":545851924},{"date":"2026-04-24","current":-9.622204,"twenty":-13.825362,"median":-12.457995,"eighty":-9.650988,"marketCap":521483535},{"date":"2026-05-01","current":-7.206485,"twenty":-13.809991,"median":-11.744798,"eighty":-9.486381,"marketCap":528794052},{"date":"2026-05-08","current":-7.639457,"twenty":-13.779732,"median":-11.111376,"eighty":-9.258769,"marketCap":562411874},{"date":"2026-05-15","current":-7.446972,"twenty":-13.702513,"median":-10.748527,"eighty":-8.300034,"marketCap":543697644},{"date":"2026-05-22","current":-7.434647,"twenty":-13.568448,"median":-10.364346,"eighty":-8.115636,"marketCap":538772846},{"date":"2026-05-29","current":-7.796965,"twenty":-13.4527,"median":-9.998785,"eighty":-7.794875,"marketCap":568321631},{"date":"2026-06-05","current":-8.053102,"twenty":-13.287949,"median":-9.784729,"eighty":-7.758816,"marketCap":585558422},{"date":"2026-06-12","current":-6.750851,"twenty":-13.127527,"median":-9.578953,"eighty":-7.536224,"marketCap":486569993},{"date":"2026-06-18","current":-6.929006,"twenty":-13.073014,"median":-9.501773,"eighty":-7.448225,"marketCap":497404547},{"date":"2026-06-26","current":-9.2886,"twenty":-13.035188,"median":-9.467948,"eighty":-7.458553,"marketCap":661400304},{"date":"2026-07-02","current":-8.166663,"twenty":-12.965993,"median":-9.467948,"eighty":-7.479819,"marketCap":584573463},{"date":"2026-07-10","current":-8.975013,"twenty":-12.944797,"median":-9.309036,"eighty":-7.532768,"marketCap":641701114},{"date":"2026-07-17","current":-8.479177,"twenty":-12.71107,"median":-9.193391,"eighty":-7.541408,"marketCap":606735052},{"date":"2026-07-24","current":-8.981683,"twenty":-12.707304,"median":-9.020605,"eighty":-7.554336,"marketCap":638746235},{"date":"2026-07-31","current":-8.723327,"twenty":-12.661785,"median":-8.978348,"eighty":-7.610114,"marketCap":628157921},{"date":"2026-08-07","current":-9.22434,"twenty":-12.557349,"median":-9.00807,"eighty":-7.636377,"marketCap":664847662},{"date":"2026-08-14","current":-8.931525,"twenty":-12.519309,"median":-9.035172,"eighty":-7.716456,"marketCap":686763011},{"date":"2026-08-21","current":-8.496488,"twenty":-12.423423,"median":-8.981683,"eighty":-7.781927,"marketCap":661400304},{"date":"2026-08-28","current":-8.778373,"twenty":-12.380686,"median":-8.974146,"eighty":-7.796268,"marketCap":681591974},{"date":"2026-09-04","current":-9.428222,"twenty":-12.300242,"median":-8.931525,"eighty":-7.867232,"marketCap":730347469},{"date":"2026-09-11","current":-8.858281,"twenty":-11.959423,"median":-8.973278,"eighty":-7.956453,"marketCap":686516771},{"date":"2026-09-16","current":-7.786468,"twenty":-11.715841,"median":-8.911516,"eighty":-7.864702,"marketCap":598855376}],"updateTime":1789644320671},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2658596039","title":"Press Release: Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2658596039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658596039?lang=en_us&edition=fundamental","pubTime":"2026-08-11 04:07","pubTimestamp":1786392420,"startTime":"0","endTime":"0","summary":"approval at the Company's Special General Meeting to be held on September. -- The Company also announced that it will hold an Extraordinary General. Shareholders' Meeting to obtain shareholder approval for the proposed","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IPO","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657666647","title":"AgomAb Therapeutics H1 EPS $(0.93)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657666647","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657666647?lang=en_us&edition=fundamental","pubTime":"2026-08-07 05:52","pubTimestamp":1786053125,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics (NASDAQ:AGMB) reported quarterly losses of $(0.93) per share.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61026366/agomab-therapeutics-h1-eps-0-93","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"AgomAb Therapeutics H1 EPS $(0.93)","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657756652","title":"Agomab FY26 H1 Net Loss Widens to €30.97 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657756652","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657756652?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:02","pubTimestamp":1786046565,"startTime":"0","endTime":"0","summary":"Agomab FY26 H1 net loss widens to 30.97 millionAgomab posted a net loss of EUR 31 million for the six months ended June 30, 2026, widening from EUR 26.9 million a year earlier.R&D expense edged up to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDL92jydC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","BK4588","BK4112","BK4007","BCDF","IE00B64PRP62.GBP","AGMB","SG9999014013.SGD","LU2210150020.SGD","IE00BKPKM429.USD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014039.USD","SG9999014005.SGD","IE00BN0W2V16.EUR","NDAQ","SG9999014021.USD","IE00B3QW5Z07.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657652239","title":"Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652239","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657652239?lang=en_us&edition=fundamental","pubTime":"2026-08-07 04:01","pubTimestamp":1786046461,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nTUA12YZKW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653726762","title":"Agomab Therapeutics Initiated at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2653726762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653726762?lang=en_us&edition=fundamental","pubTime":"2026-07-23 22:24","pubTimestamp":1784816640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings(END) Dow Jones NewswiresJuly 23, 2026 10:24 ET","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","AGMB","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653975740","title":"B. Riley Initiates AgomAb Therapeutics at Buy With $34 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2653975740","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653975740?lang=en_us&edition=fundamental","pubTime":"2026-07-23 20:22","pubTimestamp":1784809320,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics NV ADR (AGMB) has an average rating of buy and mean price target of $32.53, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653771773","title":"Analysts’ Top Healthcare Picks: AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmaceuticals (MIST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2653771773","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653771773?lang=en_us&edition=fundamental","pubTime":"2026-07-23 16:00","pubTimestamp":1784793639,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on AgomAb Therapeutics NV ADR (AGMB), Milestone Pharmac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-agomab-therapeutics-nv-adr-agmb-milestone-pharmaceuticals-mist-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-agomab-therapeutics-nv-adr-agmb-milestone-pharmaceuticals-mist-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGMB","DIVL","ARMH","LU0029874061.USD","BK4581","BK4585","DINT","XBI","HCSG","LU0128526141.USD","AADR","BK4007","XLV","APIE","LABU","SAPH","CVY","BK4588","BK4137","MIST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653185787","title":"Agomab Therapeutics Nv : B. Riley Initiates Coverage with Buy Rating; Target Price $34","url":"https://stock-news.laohu8.com/highlight/detail?id=2653185787","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653185787?lang=en_us&edition=fundamental","pubTime":"2026-07-23 10:46","pubTimestamp":1784774771,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nFWN43O16S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647047703","title":"Agomab Therapeutics NV trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2647047703","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647047703?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:56","pubTimestamp":1782762961,"startTime":"0","endTime":"0","summary":"15:51 EDT Agomab (AGMB) Therapeutics NV trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, mar...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-therapeutics-nv-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-therapeutics-nv-trading-halted-volatility-trading-pause-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","AGMB","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647304500","title":"NASDAQ Trade Halt Volatility Trading Pause at 03:51 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2647304500","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647304500?lang=en_us&edition=fundamental","pubTime":"2026-06-30 03:51","pubTimestamp":1782762704,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 03:51 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260629:nAQN2M63L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646366992","title":"European Equities Traded in the US as American Depositary Receipts Decline Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2646366992","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646366992?lang=en_us&edition=fundamental","pubTime":"2026-06-26 23:06","pubTimestamp":1782486382,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts were lower Friday morning, decreasing 0.4% to 1,883.22 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by biotech companies Evaxion  and Abivax , which gained 5.4% and 4.5% respectively. They were followed by healthcare firm Grifols  and drink and brewing giant Anheuser-Busch Inbev , which added 1.4% and 1.1%, respectively.The decliners from continental Europe were led by Agomab Therapeutics  and steel producer ArcelorMittal , which fell 3.9% and 3.5% respectively. They were followed by energy company Equinor , which was down 1.3%.From the UK and Ireland, the gainers were led by pharmaceutical company Compass Pathways  and Autolus Therapeutics , which rose 5.6% and 2.8% respectively.The decliners from the UK and Ireland were led by semiconductor company Arm  and Barclays , which shed 4% and 1.3% respectively.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARM","GRFS","AGMB","BK4158","ARMG","EQNR","BK4543","BK4007","BK4609","BUD","LU2543165471.USD","BCS","BK4139","BK4201","MT","LU0081259029.USD","BK4141","BK4207","BK4585","CMPS","IE00BMPRXQ63.HKD","BK4006","BK4521","ARMW","ABVX","EVAX","LU0348723411.USD","BK4561","IE00BMPRXN33.USD","AUTL","LU1232071149.USD","BK4588","ADRU","IE00BMPRXR70.SGD","ARMU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645915854","title":"Agomab, FDA Agree on Phase 2b Trial for Crohn's Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2645915854","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645915854?lang=en_us&edition=fundamental","pubTime":"2026-06-24 05:14","pubTimestamp":1782249240,"startTime":"0","endTime":"0","summary":"Agomab Therapeutics reached alignment with the Food and Drug Administration on the design of a Phase 2b study for patients with Crohn's disease who develop intestinal narrowings that can block food and often lead to surgery.The study will test Agomab's experimental pill, ontunisertib, against placebo in up to 320 adults, the Belgium-based company said Tuesday. Doctors will check at 24 weeks whether a scope can pass through the narrowed section of the intestine, which is a practical way to see if the blockage is easing. The trial will also follow patients to 52 weeks to track longer-term outcomes.Agomab said the protocol has been filed with the FDA and cleared a central ethics review in the U.S., and the study has Health Canada approval. The company has also submitted clinical trial applications in Europe and parts of Asia. The first patient is expected to be dosed in the second half of this year.Crohn's is a chronic progressive disease of the gastrointestinal tract. About 46% of all pa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4007","BK4231","ADC","BK4080","AGMB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645485922","title":"Agomab announces NOV-ERA study design","url":"https://stock-news.laohu8.com/highlight/detail?id=2645485922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645485922?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:18","pubTimestamp":1782245926,"startTime":"0","endTime":"0","summary":"Agomab (AGMB) announced the design of its upcoming Phase 2b NOV-ERA study with ontunisertib, its investigational oral gastro-intestinal-restricted ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-announces-nov-era-study-design-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGMB","BK4179","LU0061475181.USD","BK4007","LU1878469433.USD","NOV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859954","title":"Agomab wins FDA alignment for NOV-ERA Phase 2b design in fibrostenosing Crohn’s disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859954","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859954?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:06","pubTimestamp":1782245172,"startTime":"0","endTime":"0","summary":"Agomab secured FDA alignment on the Phase 2b NOV-ERA study design for ontunisertib in fibrostenosing Crohn’s disease.The protocol cleared central IRB review in the U.S. and received Health Canada authorization.First patient dosing is targeted for the second half of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL3YCkJP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","LU2210150020.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014013.SGD","LU2210149790.SGD","BK4585","IE00BN0W2W23.USD","SG9999014039.USD","AGMB","SG9999014005.SGD","BK4588","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","NDAQ","LU0314104364.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645859691","title":"Agomab Announces Design of Nov-Era Phase 2B Study With Ontunisertib in Fibrostenosing Crohn’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2645859691","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645859691?lang=en_us&edition=fundamental","pubTime":"2026-06-24 04:05","pubTimestamp":1782245100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA9TGKXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645029722","title":"AgomAb Therapeutics Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2645029722","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645029722?lang=en_us&edition=fundamental","pubTime":"2026-06-22 19:11","pubTimestamp":1782126660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AGMB/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 22, 2026 07:11 ET (11:11 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645026819","title":"Agomab initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2645026819","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645026819?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:05","pubTimestamp":1782122738,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio initiated coverage of Agomab (AGMB) with a Buy rating and $35 price target The firm says both of Agomab’s ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/agomab-initiated-with-a-buy-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645025530","title":"Agomab Therapeutics Nv : H.c. Wainwright Initiates Coverage With Buy Rating  and Target Price $35","url":"https://stock-news.laohu8.com/highlight/detail?id=2645025530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645025530?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:01","pubTimestamp":1782122485,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nAZN4T3J2A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","AGMB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645042865","title":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, Visteon","url":"https://stock-news.laohu8.com/highlight/detail?id=2645042865","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645042865?lang=en_us&edition=fundamental","pubTime":"2026-06-22 15:47","pubTimestamp":1782114448,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Baldwin Insurance Group, Diamondback Energy, VisteonJune 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4N42U0H9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRZ","DFTX","INTW","NBIX","LINT","VC","INTC","MRNX","LRCU","GLW","ARMK","FANG","MRNA","FMC","MUU","BYD","HCA","KLAC","AALG","KR","ENPH","BILL","DAR","ABVX","LGN","LQDA","ALGM","MULL","INCY","APGE","AGMB","FTH","KMX","LRCX","AMAT","DCH","FPS","MU","BWIN","BWXT","CNXU","MRK","CHRD","KLAG","AAL","MTDR","ALT","MRNY","DAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638550503","title":"Agomab Therapeutics holds annual general meeting, backs board reappointments","url":"https://stock-news.laohu8.com/highlight/detail?id=2638550503","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638550503?lang=en_us&edition=fundamental","pubTime":"2026-05-27 17:00","pubTimestamp":1779872448,"startTime":"0","endTime":"0","summary":"Agomab held its annual general meeting on May 26, 2026.Shareholders adopted the statutory financial statements for the year ended Dec. 31, 2025.Shareholders granted discharge to current and former directors, plus the statutory auditor, for duties performed in 2025.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nNDL8BnFDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014021.USD","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","NDAQ","LU2210150020.SGD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","BK4588","BK4112","SG9999014013.SGD","IE00BN0W2T93.GBP","LU0314104364.USD","AGMB","LU2095319765.USD","BK4007","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":47,"code":"91000000","status":"200"}]}}